Navidea Biopharmaceuticals, Inc. (NAVB)

NAVB Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	2	4.23	2.67	1.05	3.48
Short-Term Investments	0	0	0	0	0.8
Cash & Cash Equivalents	2	4.23	2.67	1.05	4.28
Cash Growth	-52.83%	58.43%	155.02%	-75.51%	-6.91%
Receivables	0	0.09	2.99	0.9	0.02
Inventory	0.43	0.15	0.17	-0.9	0
Other Current Assets	0.78	0.91	0.7	1.87	0.68
Total Current Assets	3.2	5.38	6.53	2.92	4.97
Property, Plant & Equipment	0.16	0.25	0.38	0.31	0.16
Intangible Assets	1	0.79	0.62	0.39	0.43
Other Long-Term Assets	0.01	0.23	0.23	0.54	1.44
Total Long-Term Assets	1.17	1.26	1.23	1.24	2.03
Total Assets	4.37	6.64	7.76	4.15	7.01
Accounts Payable	2.12	1.42	1.16	1.11	0.42
Deferred Revenue	0.8	0.7	0.7	0.7	0.87
Current Debt	0.56	0.73	1.04	0.56	0.32
Other Current Liabilities	6.46	2.45	1.81	1.45	1.77
Total Current Liabilities	9.94	5.3	4.72	3.82	3.38
Long-Term Debt	1.87	0.02	0.3	0.51	0.47
Other Long-Term Liabilities	0.7	0.7	0.7	0.7	0.76
Total Long-Term Liabilities	2.57	0.72	1	1.21	1.23
Total Liabilities	12.51	6.02	5.71	5.03	4.61
Total Debt	2.43	0.75	1.34	1.07	0.32
Debt Growth	224.82%	-43.92%	25.03%	238.17%	-86.57%
Common Stock	0.22	0.22	0.22	0.21	0.2
Retained Earnings	-388	-370.79	-359.06	-347.67	-336.72
Comprehensive Income	0	0	-4.97	0	-0
Shareholders' Equity	-8.44	-0.11	1.32	-1.61	1.73
Total Liabilities and Equity	4.37	6.64	7.76	4.15	7.01
Net Cash / Debt	-0.44	3.48	1.33	-0.02	3.96
Net Cash / Debt Growth	-	160.96%	-	-	-1.92%
Net Cash Per Share	-0.01	0.12	0.06	-0.00	0.46
Working Capital	-6.74	0.08	1.81	-0.9	1.6
Book Value Per Share	-0.29	-0.00	0.06	-0.11	0.20

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.